Home › Targets › KIT

KIT (3 companies · 7 programs)

Companies with an active program directed at KIT.

Celldex Therapeutics, Inc. CLDX

barzolvolimab — Chronic Spontaneous Urticaria Phase 3
barzolvolimab — Symptomatic Dermographism Phase 3
barzolvolimab — Prurigo Nodularis Phase 2
barzolvolimab — Atopic Dermatitis Phase 2
barzolvolimab — Chronic Inducible Urticaria Phase 3

Cogent Biosciences, Inc. COGT

bezuclastinib — Gastrointestinal Stromal Tumor NDA Submitted

ENANTA PHARMACEUTICALS INC ENTA

EDP-978 — Chronic Spontaneous Urticaria Phase 1